ArticlePsycho-oncology2026
Sleep Disturbance at Cancer Diagnosis and Its Associations With Depressive Symptoms and Systemic Inflammatory Burden.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSleep disturbance is highly prevalent among cancer patients and closely associated with depressive symptoms. However, it remains unclear whether sleep problems present at cancer diagnosis primarily reflect depression or also indicate an underlying biological susceptibility.
aimThis study aimed to examine the relationships between sleep disturbance, depressive symptoms, and systemic inflammatory-nutritional burden in newly diagnosed, treatment-naïve cancer patients.
methodsIn this cross-sectional study, sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) in patients at diagnosis before oncological treatment. Poor sleep quality (PSQ) was defined as PSQI ≥ 5, and sleep disturbance severity was evaluated using the total PSQI score. Depressive symptoms were measured with the Hospital Anxiety and Depression Scale-Depression subscale (HADS-D). Systemic inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR) and lactate dehydrogenase-to-albumin ratio (LAR), were calculated from routine laboratory data. Multivariable logistic regression and generalized linear models assessed factors associated with PSQ and sleep disturbance severity, respectively. Receiver operating characteristics (ROC) analyses evaluated the discriminatory performance of depressive symptoms and inflammatory indices. Stratified analyses were conducted according to depression status (HADS-D < 8 vs. ≥ 8).
resultsSleep disturbance was highly prevalent at diagnosis. Depressive symptom burden was independently associated with both PSQ and higher PSQI scores. Importantly, systemic inflammatory indices remained independently associated with sleep disturbance after adjustment for depressive symptoms and clinical variables. NLR showed moderate discriminatory ability for PSQ, while LAR was independently associated with sleep disturbance severity. ROC analyses indicated that depressive symptoms and inflammatory burden jointly improved discrimination of PSQ. In stratified analyses, LAR remained significantly associated with PSQI scores regardless of depression status.
conclusionSleep disturbance at cancer diagnosis is independently associated with both depressive symptoms and systemic inflammatory-nutritional burden, suggesting that it may reflect not only psychological distress but also underlying biological processes. Routine sleep assessment alongside inflammatory markers may help identify vulnerable patients and support early supportive care planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.